Explore Our Network

AegisCN LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute neurological injury and stroke. The company’s lead therapeutic candidate, CN-105, is a proprietary neuroprotective peptide designed to reduce inflammation, limit secondary brain injury, and improve recovery following central nervous system events. AegisCN’s development efforts have centered on high-impact medical conditions with significant unmet need, including intracerebral hemorrhage (hemorrhagic stroke) and traumatic brain injury (TBI). CN-105 has advanced through Phase 1 and Phase 2 clinical studies, reflecting the company’s commitment to translating cutting-edge neuroscience into real-world treatment options for patients and providers.

ALA Scientific Instruments, Inc. is dedicated to advancing life science through innovative instrumentation. With over thirty years of experience, the company provides researchers with the tools necessary for challenging experiments in biophysics and cellular electrophysiology.

This organization specializes in integrated, science-based treatment and diagnostics for Alzheimer’s, dementia, and cognitive decline. Utilizing a precision medicine approach, the center combines advanced AI analysis, biomarker-driven planning, and multimodal therapies including brain imaging, neurocognitive testing, and over 50 clinical and supportive treatment modalities. The care model addresses both the root causes and neuropsychiatric aspects of cognitive impairment, delivered by a multidisciplinary team with expertise in functional, regenerative, and collaborative behavioral medicine.

The American Institutes for Research® (AIR) is a nonpartisan, not-for-profit organization that conducts behavioral and social science research and delivers technical assistance to solve some of the most urgent challenges in the U.S. and around the world. From education to workforce development, to healthcare service and delivery, community safety and well-being, readiness, and resilience, our work drives toward practical solutions that improve lives for service members, families and communities. We do this work because we are dedicated to closing gaps to opportunity and access across the lifespan. At AIR, we know that improving outcomes begins with systems that work for everyone, so we lead with expertise, follow the evidence, and never stop drawing new connections to fulfill our mission.

ANT5 Co., Ltd. is a startup originating from Yamaguchi University dedicated to the research and development of medical devices for patients suffering from severe brain diseases. The company aims to save lives and alleviate suffering through advanced technology, with a vision to become the global standard in sensor and cooling technology for brain disease treatment by 2030.

Apertur develops an app-based solution that assesses brain health through real-time analysis of pupillary dynamics using the smartphone camera. The approach provides metrics and patterns to track and potentially enhance brain performance, supporting individuals in monitoring and optimizing their mental state. In addition, Apertur develops a traumatic brain injury in the moment diagnostic app that leverages the same core technology.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

BioResponse LLC (BR) focuses on the research, development, and manufacturing of patented nanoscale drug formulations. The company’s mission for over 25 years has been its commitment to develop future therapeutic uses of small molecule indoles . BR has developed two patented drug product candidates. Both oral and IV formulations treat acute Central Nervous System (CNS) injury by forming nanoparticles to deliver the lead API. Boulder BioScience (BBS), LLC, the sister company of BR, is focused on the early therapy of brain injury and control of trauma related thrombosis. BBS’s mission is to advance breakthrough science for acute-care indications filling critical, unmet needs in Military Medicine. The drug candidates provide promising new treatments for traumatic brain injury (TBI), Concussion, Blast Injury, and Acute Ischemic Stroke (AIS). Advancement of drug candidates for EMT administered, post-injury use will provide immediate protection of the Blood Brain Barrier, prevent Cerebral Edema, minimize Brain Contusions, and contribute to neurocognitive recovery.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

BrainBox Solutions develops AI-enabled, multi-modality diagnostic and prognostic tools for mild traumatic brain injury that integrate blood-based biomarker panels, digital neurocognitive assessments, and point-of-care device technology. The company's platform is validated through large, multi-site clinical trials covering adults, geriatrics, and pediatrics, with an emphasis on evidence-based evaluation, risk stratification, and real-world clinical adoption. Research partnerships, grant funding, and a strong intellectual property portfolio support their objective of providing diagnostic and prognostic solutions for brain injury across diverse care settings and patient populations.

BrainHQ is a leading brain training platform developed by top neuroscientists, designed to enhance cognitive functions through scientifically proven exercises. It offers a flexible and personalized approach to brain fitness, adapting to individual needs and lifestyles, and is backed by extensive research demonstrating its effectiveness in improving memory, attention, and overall brain health. The platform also provides classes and webinars to educate users on brain health and cognitive training. With over 100 published studies validating its benefits, BrainHQ continues to evolve through ongoing research.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Charles River Analytics is dedicated to developing human-centered intelligent systems that enhance military performance, ensure homeland security, and transform healthcare through advanced technology. With a strong focus on AI, robotics, and human-centered computing, the company aims to solve complex challenges faced by government and commercial sectors. The company also emphasizes its commitment to corporate social responsibility, employee ownership, and innovative training solutions.

Chronic Trace develops a research-stage platform that turns video from a commodity smartphone into objective, baseline-relative indices of brain function. A single short capture fuses involuntary signals (oculomotor and postural) with task-based measures (cognitive and reaction) into one calibrated index, the Trace Score, for decision support. The live focus today is concussion and mild TBI; the same architecture is patent-staked to extend toward stroke triage, psychiatric, and neurodegenerative monitoring. The platform is in active validation, backed by 15 U.S. patents pending, with encrypted data handling at rest and in transit. It is decision-support and research-stage, not a cleared medical device, and its outputs are intended for interpretation by qualified health professionals.

Cogwear is a US-based neurotechnology company specializing in wearable EEG devices that deliver clinical-grade brain monitoring and analytics outside traditional laboratory or clinical environments. Founded in collaboration with academic neuroscience experts and supported by organizations such as the National Science Foundation, Cogwear's mission is to provide scalable, real-time cognitive and mental health insights for medical, athletic, research, and commercial settings. Their technology platform employs advanced dry EEG sensors and machine learning algorithms for applications including early detection of Alzheimer's disease, behavioral health assessment, concussion monitoring, and neuromarketing analytics. The company is committed to meeting FDA requirements for medical-grade devices while expanding its impact through industry partnerships and scalable manufacturing.

Cooper University Health Care is a regional academic health system recognized for comprehensive clinical services, advanced multidisciplinary care, specialized surgery, and robust research in South Jersey. It provides integrated healthcare across general and specialty domains, including cancer, neurosciences, cardiology, trauma, genetics, addiction medicine, and complex surgical procedures, supported by leading technologies and a network of modern facilities.

Crainio is a UK-based medical technology company focused on revolutionizing the measurement of intracranial pressure (ICP) through a non-invasive, real-time, and affordable device. Their mission is to improve the diagnosis and treatment of traumatic brain injury (TBI) by providing clinicians with continuous ICP monitoring without the need for invasive procedures. Using low-power infrared light and advanced machine learning algorithms, Crainio's technology aims to make ICP measurement accessible, safe, and effective for a wide range of healthcare settings.